BWA
TLX

Basecamp Wealth Advisors’s Telix Pharmaceuticals TLX Stock Holding History

Basecamp Wealth Advisors’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.5K Buy
390
+114
+41% +$1.16K ﹤0.01% 1202
2026
Q1 		$2.64K Hold
276
– – ﹤0.01% 1340
2025
Q4 		$2.07K Buy
+276
New +$2.66K ﹤0.01% 1347

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Basecamp Wealth Advisors's TLX Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Telix Pharmaceuticals (TLX) stake by 41% in Q2 2026, buying an estimated $1.16K and bringing the position to 390 shares worth $4.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1202.

Basecamp Wealth Advisors first reported a position in TLX in Q4 2025 and has held it in 3 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Basecamp Wealth Advisors held 390 shares of Telix Pharmaceuticals worth $4.5K as of Q2 2026.
  • Basecamp Wealth Advisors bought 114 Telix Pharmaceuticals shares in Q2 2026, an estimated $1.16K.
  • Telix Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1202 holding.
  • Basecamp Wealth Advisors first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.